Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07586202 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableLead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLCTrial sites expanded: 20 → 23 locations · Eligibility criteria expanded, about 10 words · Secondary endpoints: details revised at 2 of 5 entriesShow 3 more changesShow less
Trial sites expanded: 20 → 23 locations
Eligibility criteria expanded, about 10 words
Secondary endpoints: details revised at 2 of 5 entries
MinorTrial sites expanded: 8 → 20 locationsv5
MinorTrial sites expanded: 1 → 8 locationsStart date changed from estimate of Jul 17, 2026 to Jul 28, 2026v4Show 1 more changeShow less
Start date changed from estimate of Jul 17, 2026 to Jul 28, 2026
NotableRecruitment openedStudy sites: 0 to 1 · Completion date: Apr 1, 2028 to Apr 3, 2028v3Show 2 more changesShow less
Study sites: 0 to 1
Completion date: Apr 1, 2028 to Apr 3, 2028
MinorStart date: Jul 28, 2026 to Jul 17, 2026v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal growth factor receptor (EGFR) mutated, Stage II-IIIB non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. NSCLC may occur due to mutations (changes) in many genes, including EGFR.